ACCESS-Leukemia for Adults with Acute Leukemia or MDS

This study, called ACCESS-Leukemia, is looking at how screening for health-related social needs and early social work help might benefit adults with acute leukemia or a type of myelodysplastic syndrome (MDS). These social needs, like financial hardship or housing issues, can impact health. Researchers want to see if this intervention, which includes a survey about your social needs and a social work consultation, is practical and helpful. They will compare this approach to standard care. The study aims to understand if this early support can improve outcomes for patients. You may be able to join if you are an adult (18 or older) newly referred to an outpatient adult leukemia treatment program with certain diagnoses of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or intermediate/high-risk MDS.

Study design
This is an interventional study with a planned enrollment of 80 participants. It compares a social needs screening and social work consultation to usual care.
What's involved
You would complete a screening survey about your health-related social needs and have a social work consultation within two weeks of joining. You will also complete baseline assessments.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes like enrollment rates, survey completion, and intervention acceptability for up to 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07671209

Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~80 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:ACCESS-Leukemia

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of eligible participants enrolling
Measured over 24 weeks
+2 more outcomes measured
Leukemia, Acute
1 sites across 1 states
Massachusetts1
  • Michelle H Lee, MD · PRINCIPAL_INVESTIGATOR · Mass General Brigham Cancer Institute

Opens a ready-to-send draft in your own email app — review before sending.

  • Rate of eligible participants enrolling24 weeks

    Number of participants that are eligible to enroll on the protocol

  • Rate of HRSN survey completion24 weeks

    Number of participants that complete the HRSN screen before 3rd leukemia clinic visit from time of study enrollment

  • Acceptability of interventionup to week 24

    Satisfaction rating of participants who received the intervention on the Client Satisfaction Questionnaire (CSQ). The CSQ includes 4 questions and is scored on a 4-point Likert scale with higher score indicating higher satisfaction. The program will be deemed acceptable if mean average score of participants is 12 or higher (out of 16).